Table 2.

The demographic data and characteristics of comorbid MFS and MG (5 cases).

characteristics	Case 1	Case 2	Case 3	Case 4	Case 5
Author (yr)	Mak W(2005)	Silverstein MP(2008)	Lau KK(2009)	Tanaka Y(2016)	Our case
Population	Hong Kong/China	USA	Hong Kong/China	Japan	China
Gender	M	M	F	F	M
Age	40	43	84	69	72
Preceding factors	+	-	+	-	-
Clinical characteristics	Limb weakness, areflexia, ptosis, ophthalmoplegia	Ataxia, areflexia, ophthalmoplegia, ptosis	weakness, areflexia, ptosis, ophthalmoplegia, dysphagia, dysarthria, respiratory failure	Acute bilateral ptosis, ophthalmoplegia, ataxic gait, and areflexia	Acute bilateral ptosis, ophthalmoplegia, diplopia
Albumino-cytologic dissociation	+	-	+	-	+
Nerve conduction	+	-	+	-	+
RNS	-	+	+	+	+
Anti-AChR antibody	+	+	+	+	+
Anti-GQ1b antibody	+	-	-	+	+
Edrophonium chloride
Treatment	plasmapheresis, pyridostigmine	-	Pyridostigmine, IVIG	IVIG, Steroid	pyridostigmine, IVIG
Thymectomy	-	-	-	-	+
Prognosis	1	0	0	1	0

M- Male, F - Female, MG - Myasthenia gravis, MFS - Miller Fisher Syndrome, IVIG - intravenous immunoglobulin, RNS - repetitive nerve stimulation, Functional outcome was ranked according to the adopted scale by Hughes: 0, healthy; 1, minor symptoms or signs, able to run; 2, able to walk >5 m without assistance, but unable to run; 3, able to walk >5 m with assistance; 4, bed- or chair-bound; 5, requiring assisted ventilation for at least part of the day; and 6, dead. “+” indicates the patient had precipitating factors from infectious disease.”-” indicates the patient did not have precipitating factors from infectious disease. As for the other parameters, “+” indicates positive findings, and “-” indicates negative findings